Article PDF first page preview

First page of Development and Validation of a Predictive Model for SLNB Exemption in DCIS Patients

Introduction: There is no uniform standard on whether total mastectomy for ductal carcinoma in situ (DCIS) can exempt sentinel lymph node biopsy (SLNB). This study attempts to find the risk factors for the underestimation of DCIS pathology, and establish the corresponding prediction model to screen suitable DCIS patients for exemption from SLNB. Methods: A total of 826 patients with DCIS met the inclusion criteria. Logistic regression identified lesion size, Ki-67, estrogen receptor (ER) status, HER2 status, histological grade, and diagnostic method as independent predictors of pathological underestimation (P < 0.05). Based on these variables, a predictive model was developed: P = 0.354 × lesion size + 0.017 × Ki-67 + 1.186 × ER − 2.501 × diagnosis method (1) − 1.575 × diagnosis method (2) − 0.050 × HER2 (1) − 1.578 × HER2 (2) + 1.160 × grade (1) + 1.497 × grade (2) − 2.418 (if age <50) − 0.156 × 1 (if age >50) The model showed good performance with a sensitivity of 79.2%, specificity of 73.8%, and overall accuracy of 76.2%. The AUC was 0.856 (95% CI: 0.831–0.881, P < 0.001). Subgroup analyses indicated that age, presence of mass, ER, HER2, tumor grade, and histological grade significantly affected model performance (AUC = 0.787; sensitivity = 0.695; specificity = 0.753). Stratified analysis showed higher sensitivity in patients <50 years (0.840 vs. 0.656), and higher AUC in ER-positive cases (0.865). In HER2-based analysis, only the presence of a mass remained significant. Mass-based analysis revealed all variables except age were significant, with a higher AUC in patients without a mass (0.784 vs. 0.727). Conclusion: This study developed a predictive model based on lesion size, Ki-67, ER status, HER2 status, histological grade, and diagnostic method to assess the risk of pathological underestimation in DCIS. The model demonstrated good predictive performance (AUC = 0.856) with high sensitivity and specificity, indicating its potential clinical utility. Subgroup analyses revealed that factors such as age, presence of a mass, and ER status influenced model performance, with particularly better accuracy observed in patients under 50 and those with ER-positive tumors. This model may serve as a useful tool to support clinical decision-making, especially in preoperative evaluation of invasive potential in DCIS patients.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.